POSITRON CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that POSITRON CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $461.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $587.5K | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | $259.0K | Mar 31, 2015 |
| FY2014 | Sep 30, 2014 | $396.0K | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | $355.0K | Mar 31, 2015 |
| FY2014 | Mar 31, 2014 | $456.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $476.0K | Mar 31, 2015 |
| FY2014 | Sep 30, 2013 | $351.0K | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | $432.0K | Mar 31, 2015 |
| FY2014 | Mar 31, 2013 | $371.0K | Mar 31, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $461.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $587.5K | Mar 31, 2026 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.11M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($342.0K) | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | $27.0K | Mar 31, 2015 |
| FY2014 | Sep 30, 2014 | $4.0K | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | $45.0K | Mar 31, 2015 |
| FY2014 | Mar 31, 2014 | $28.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $164.0K | Mar 31, 2015 |
| FY2014 | Sep 30, 2013 | $121.0K | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | $14.0K | Mar 31, 2015 |
| FY2014 | Mar 31, 2013 | $125.0K | Mar 31, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.60M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.38M) | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | $86.0K | Mar 31, 2015 |
| FY2014 | Sep 30, 2014 | $1.44M | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | $201.0K | Mar 31, 2015 |
| FY2014 | Mar 31, 2014 | $861.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $3.43M | Mar 31, 2015 |
| FY2014 | Sep 30, 2013 | $1.39M | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | $1.09M | Mar 31, 2015 |
| FY2014 | Mar 31, 2013 | $1.20M | Mar 31, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.50M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.21M) | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | ($2.74M) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($3.34M) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | ($4.72M) | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | ($4.39M) | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | ($14.44M) | Apr 6, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $471.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $564.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $940.0K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $1.32M | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | $1.28M | Apr 6, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.70M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.73M) | Mar 31, 2026 |
| FY2013 | Dec 31, 2013 | ($3.05M) | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | ($2.24M) | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | ($4.08M) | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | ($4.69M) | Apr 6, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $26.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $16.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $73.0K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $10.0K | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | $238.0K | Apr 6, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.00M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.80M | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | $1.87M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $3.88M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $2.69M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $2.31M | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | $5.17M | Apr 6, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.56M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.46M | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | $2.71M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $15.12M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $8.88M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $5.18M | Apr 23, 2013 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($656.7K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($510.3K) | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | ($837.0K) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($11.24M) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | ($6.19M) | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | ($2.87M) | Apr 23, 2013 |
| FY2012 | Dec 31, 2010 | ($86.0K) | Apr 23, 2013 |
| FY2011 | Dec 31, 2009 | ($6.96M) | Apr 6, 2012 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $346.0K | Mar 31, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($144.94M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($134.33M) | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | ($126.02M) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($123.43M) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | ($116.33M) | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | ($108.37M) | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | ($102.25M) | Apr 6, 2012 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $208.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $1.74M | Mar 31, 2015 |
| FY2014 | Dec 31, 2012 | $243.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2011 | $1.0K | Mar 31, 2014 |
| FY2012 | Dec 31, 2010 | $1.14M | Apr 23, 2013 |
| FY2011 | Dec 31, 2009 | $165.0K | Apr 6, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.7K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $24.3K | Mar 31, 2026 |
| FY2012 | Dec 31, 2012 | $689.0K | Apr 23, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 32.80M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 27.31M | Mar 31, 2026 |
| FY2014 | Dec 31, 2014 | 5.55B | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 1.45B | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 1.45B | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | 788.33M | Apr 23, 2013 |
| FY2011 | Dec 31, 2010 | 782.73M | Apr 6, 2012 |